Correction to: Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015–2022): 2022 interim analysis.

MLA

Mercuri, Eugenio, et al. “Correction to: Safety and Effectiveness of Ataluren in Patients with Nonsense Mutation DMD in the STRIDE Registry Compared with the CINRG Duchenne Natural History Study (2015–2022): 2022 Interim Analysis.” Journal of Neurology, vol. 270, no. 9, Sept. 2023, p. 4583. EBSCOhost, https://doi.org/10.1007/s00415-023-11864-2.

APA

Mercuri, E., Osorio, A. N., Muntoni, F., Buccella, F., Desguerre, I., Kirschner, J., Tulinius, M., de Resende, M. B. D., Morgenroth, L. P., Gordish-Dressman, H., Johnson, S., Kristensen, A., Werner, C., Trifillis, P., Henricson, E. K., & McDonald, C. M. (2023). Correction to: Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015–2022): 2022 interim analysis. Journal of Neurology, 270(9), 4583. https://doi.org/10.1007/s00415-023-11864-2

Chicago

Mercuri, Eugenio, Andrés Nascimento Osorio, Francesco Muntoni, Filippo Buccella, Isabelle Desguerre, Janbernd Kirschner, Már Tulinius, et al. 2023. “Correction to: Safety and Effectiveness of Ataluren in Patients with Nonsense Mutation DMD in the STRIDE Registry Compared with the CINRG Duchenne Natural History Study (2015–2022): 2022 Interim Analysis.” Journal of Neurology 270 (9): 4583. doi:10.1007/s00415-023-11864-2.